Nivolumab with ipilimumab for untreated recurrent or metastatic squamous cell cancer of the head and neck cancer [ID1429]

  • Discontinued
  • GID-TA10512
Timelines for this appraisal are to be confirmed. Further information regarding the scheduling of this appraisal will be available in due course.